Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 1903-1917
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.1903
Table 2 Ongoing randomized controlled trials comparing surgery alone with neoadjuvant therapy followed by surgery for resectable pancreatic cancer
Trial name
NCT number
Estimated enrollment
Treatment arm
Primary endpoint
Study start date
Estimated primary completion date
Estimated study completion date
ICI20-00047NCT05181605II/IIINot yet recruiting116FOLFIRINOX and SBRT with surgeryOSJanuary 2022 January 2023 December 2024
Upfront surgery
CISPD-1NCT03750669IIRecruiting416nPt/GEM and mFOLFIRINOX with surgeryDFSOctober 2018October 2023October 2024
Upfront surgery
A021806NCT04340141IIIRecruiting352mFOLFIRINOX with surgeryOSJuly 2020January 2026November 2030
Upfront surgery
PREOPANCNCT04927780IIIRecruiting378mFOLFIRINOX with surgeryOSSeptember 2021February 2026July 2029
Upfront surgery
AIO-PAK-0313NCT02047513IIActive, not recruiting1271nPt/GEM with surgeryDFSJuly 2015April 20212October 20223
Upfront surgery
NorPACT-1NCT02919787II/IIIActive, not recruiting140FOLFIRINOX with surgery1-yr OSSeptember 2016October 2022April 2026
Upfront surgery
NEOPACNCT01314027IIITerminated381GEM/oxaliplatin with surgeryPFSSeptember 2009December 20182May 20193
Upfront surgery
NEOPANCT01900327IIITerminated321GEM and EBRT with surgery3-yr survival rateFebruary 2014 November 20162July 20173
Upfront surgery
NEOPAC/IPC 2011-002NCT01521702IIICompleted21GEM/Oxaliplatin with surgeryPFSDecember 2011 February 20152February 20153
Upfront surgery
NEPAFOXNCT02172976II/IIICompleted401FOLFIRINOX with surgerymOSNovember 2014 January 20202May 20203
Upfront surgery